Table 3.
Breakdown of Cost and QALYs Compared to Clinical Risk Alone
| Cost/QALY Category | Absolute Value | Incremental Value | |
|---|---|---|---|
| 21-Gene Assay | Clinical Risk Alone | 21-Gene Assay vs Clinical Risk Alone | |
| Costs | |||
| Genomic tests | £2580 | £0 | £2580 |
| Chemo-endocrine therapy | £1225 | £1850 | -£625 |
| Short-term AEs | £170 | £284 | -£114 |
| Recurrence-free | £1332 | £1325 | £7 |
| Local recurrence | £239 | £283 | -£44 |
| Distant recurrence | £12,142 | £14,377 | -£2235 |
| AML | £74 | £127 | -£53 |
| Terminal care | £1977 | £2012 | -£36 |
| QALYs by health state | |||
| Recurrence-free | 12.574 | 12.354 | 0.220 |
| Distant recurrence | 0.296 | 0.352 | −0.055 |
| AML | 0.000 | 0.001 | −0.001 |
| Short-term AEs | −0.006 | −0.010 | 0.004 |
Abbreviations: AE, adverse event; AML, acute myeloid leukemia; QALY, quality-adjusted life-year.